Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

Depress Anxiety

Center for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33613, USA.

Published: March 2003

Download full-text PDF

Source
http://dx.doi.org/10.1002/da.10035DOI Listing

Publication Analysis

Top Keywords

neuronal nicotinic
4
nicotinic receptor
4
receptor inhibition
4
inhibition treating
4
treating mood
4
mood disorders
4
disorders preliminary
4
preliminary controlled
4
controlled evidence
4
evidence mecamylamine
4

Similar Publications

The stoichiometry of the α4β2 neuronal nicotinic acetylcholine receptors determines the pharmacological properties of the neonicotinoids, and recently introduced butenolide and sulfoximine.

Neurotoxicology

January 2025

Laboratoire Physiologie, Ecologie and Environnement (P2E), Université d'Orléans, UR 1207, USC-INRAE 1328, 1 rue de Chartres, 45067 Orléans, France; Institut Universitaire de France (IUF), 1 rue Descartes 75005 Paris, France. Electronic address:

Although neonicotinoids were considered safe for mammals for many decades, recent research has proven that these insecticides can alter cholinergic functions by interacting with neuronal nicotinic acetylcholine (ACh) receptors (nAChRs). One such receptor is the heteromeric α4β2 nAChR, which exists under two different stoichiometries: high sensitivity and low sensitivity α4β2 nAChRs. To replace these insecticides, new classes of insecticides have been developed, such as, sulfoximine, sulfoxaflor, and the butanolide, flupyradifurone.

View Article and Find Full Text PDF

Regulation of Dopamine Release by Tonic Activity Patterns in the Striatal Brain Slice.

ACS Chem Neurosci

January 2025

Departments of Psychiatry and Neurology, Division of Molecular Therapeutics, New York State Psychiatric Institute, Columbia University Medical Center, New York, New York 10032, United States.

Voluntary movement, motivation, and reinforcement learning depend on the activity of ventral midbrain neurons, which extend axons to release dopamine (DA) in the striatum. These neurons exhibit two patterns of action potential activity: low-frequency tonic activity that is intrinsically generated and superimposed high-frequency phasic bursts that are driven by synaptic inputs. acute striatal brain preparations are widely employed to study the regulation of evoked DA release but exhibit very different DA release kinetics than recordings.

View Article and Find Full Text PDF

Objectives: The current gold standard for immunofluorescent (IF) visualization of neuromuscular junctions (NMJs) in muscle utilizes frozen tissue sections with fluorescent conjugated antibodies to demarcate neurons and IF alpha-bungarotoxin (α-BTX) to demarcate motor endplates. Frozen tissue sectioning comes with inherent inescapable limitations, including cryosectioning artifact and limited sample shelf-life. However, a parallel approach to identify NMJs in paraffin-embedded tissue sections has not been previously described.

View Article and Find Full Text PDF

Background: R-Glabridin is a major flavonoid of licorice (Glycyrrhiza glabra) root and known to modulate GABAA receptors, which are targets of many clinical hypnotics. However, R-glabridin hypnotic activity has not been reported in animals.

Methods: Inverted photomotor responses (IPMRs) were used to assess the hypnotic effects of natural R-glabridin and synthetic R/S-glabridin in wild-type zebrafish larvae and transgenic larvae lacking functional GABAA receptor β3 subunits (β30/0).

View Article and Find Full Text PDF

Galantamine-Memantine Combination in the Treatment of Parkinson's Disease Dementia.

Brain Sci

November 2024

Department of Public Safety and Correctional Services, Baltimore, MD 21215, USA.

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects over 1% of population over age 60. It is defined by motor and nonmotor symptoms including a spectrum of cognitive impairments known as Parkinson's disease dementia (PDD). Currently, the only US Food and Drug Administration-approved treatment for PDD is rivastigmine, which inhibits acetylcholinesterase and butyrylcholinesterase increasing the level of acetylcholine in the brain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!